EP0573479A1 - Preparation par recombinaison d'une enzyme tar chimere pour une therapie destinee a l'infection par le vih - Google Patents

Preparation par recombinaison d'une enzyme tar chimere pour une therapie destinee a l'infection par le vih

Info

Publication number
EP0573479A1
EP0573479A1 EP92905231A EP92905231A EP0573479A1 EP 0573479 A1 EP0573479 A1 EP 0573479A1 EP 92905231 A EP92905231 A EP 92905231A EP 92905231 A EP92905231 A EP 92905231A EP 0573479 A1 EP0573479 A1 EP 0573479A1
Authority
EP
European Patent Office
Prior art keywords
arabinofuranosyl
sequence
purine
enzyme
chimaera
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92905231A
Other languages
German (de)
English (en)
Inventor
Brian Huber
Cynthia Ann Richards
Jean Louise Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of EP0573479A1 publication Critical patent/EP0573479A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to molecular chimaeras. infective virions, to methods of their construction, to pharmaceutical formulations containing them, to their use in therapy, particularly virus-directed enzyme prodrug therapy particularly in the treatment of HIV, and to the use of agents which can be catalysed by a heterologous enzyme to cytotoxic or cytostatic metabolites, such as purine arabinosides and substituted pyrimidines in virus-directed enzvme prodrug therapy, in a mammalian host (e.g. human).
  • a mammalian host e.g. human
  • AIDS is an immunosuppressive or immunodestructive disease that predisposes subjects to fatal opportunistic infections. Characteristically, AIDS is associated with a progressive depletion of T-cells, especially the helper-inducer subset bearing the OKT surface marker.
  • HIV Human immunodeficiency virus
  • HIV is cytopathic and appears to preferentially infect and destroy T-cells bearing the OKT 4 marker, and it is now generally recognised that HIV is the etiological agent of AIDS.
  • HIV human immunodeficiency virus
  • the human immunodeficiency virus is composed of a complex genome requiring host-cellular transcriptional factors and viral encoded regulatory peptides for viral gene expression and replication.
  • viral rtructural genes i.e. gag, pol, and env
  • HIV also contains at least six regulatory genes (i.e. TAT, rev, vif, nef, upr and upu) which are synthesized from either nascent or spliced message.
  • the TAT gene product has been shown to be a potent transactivator of HIV gene expression and an essential component for the establishment of a productive viral infection.
  • the HIV target sequence for direct or indirect TAT gene product interactions is designated TAR and is located between -17 and +80bp in the 5' long terminal repeat (base pairs numbered relative to the transcription initiation site). More specifically, the TAR sequence most critical for the direct or indirect interactions with the TAT gene product may be located between +1 and +43 in the 5' long terminal repeat.
  • the TAR sequence is present in the HIV proviral DNA as well as in the 5' untranslated portion of all viral mRNAs.
  • TAT gene product may also influence cellular gene expression and, as such, may also contribute directly to the pathobiology associated with AIDS, such as Kaposi's sarcoma.
  • Transgenic animals containing a transgene composed of the HIV TAT gene developed dermal lesions resembling Kaposi's sarcoma. These data suggest that Kaposi's sarcoma, which occurs in approximately 25% of AIDS patients, may not result from the indirect immunodeficient state, but rather, may be directly and casually associated with expression of HIV TAT.
  • TAT/TAR interactions can increase HIV gene expression by over 1000- fold, and as such, is essential for a productive viral infection.
  • Gene therapy involves the stable integration of new genes into particular target cells and the expression of those genes, once thev are in place, to alter the phenotype of that particular target cell (for review see Anderson,W.F. Science 226: 401-409, 1984; McCormick, D. Biotechnology 3: 690-693, 1985).
  • Gene therapy may be beneficial for the treatment of genetic disease and involve the replacement of one defective or missing enzyme, such as hypoxanthine-guanine phosphoribosyl transferase in Lesch Nyhan disease; purine nucleoside phosphorylase in severe immunodeficiency disease and adenosine deaminase in severe combined immunodeficiency disease.
  • a molecular chimaera comprising a transcriptional regulatory sequence (TRS) which is selectively activated in target cells, such as HIV infected T-cells: this controls the expression of a heterologous enzyme.
  • TRS transcriptional regulatory sequence
  • This molecular chimaera may be manipulated via suitable vectors and incorporated into an infective virion.
  • an infective virion containing the molecular chimaera to a mammalian host (eg. human)
  • the enzyme is selectively expressed in the target cell.
  • Administration of compounds which are selectively metabolised by the enzyme into metabolites which are either further metabolised to, or are in fact cytotoxic or cytostatic agents can then be achieved in situ.
  • Molecular chimaera (recombinant molecules comprised of unnatural combinations of genes or sections of genes), and infective virions (complete viral particles capable of infecting appropriate host cells) are well known in the art of molecular biology and are further described hereinafter.
  • EPO 334 301 describes recombinant retroviruses capable of eliciting selective killing of HIV- infected cells in the presence of nucleoside analogues ACV, AZT or ddC. These compounds mav be modified to cytotoxicity by herpes simplex virus thymidine kinase (HSVTK) encoded by the recombinant retrovirus . Selectively is obtained by placing the HSVTK under control of an HIV tat dependent promoter which will only be expressed in HIV infected cells.
  • HSVTK herpes simplex virus thymidine kinase
  • a number of enzyme prodrug combinations may be used; providing the enzyme is capable of selectively activating the administered compound either directly or through an intermediate to a cytostatic or cytotoxic metabolite.
  • the choice of compound will depend on the enzyme system used, but must be selectively metabolised by the enzyme either directly or indirectly to a cytotoxic or cytostatic metabolite.
  • heterologous enzyme refers to an enzyme that is derived from or associated with a species which is different from that which will display the appropriate characteristics of selectivity.
  • VZV varicella zoster virus
  • TK thymidine kinase
  • Certain purine and pyrimidine analogues particularly those of Formulae (I) and (II) as hereinafter defined are converted to cytotoxic or cytostatic metabolites in specific mammalian cells which are genetically modified to selectively express VZV thymidine kinase.
  • 9-( ⁇ -D-arabinofuranosyl)-6-methoxy-9H-purine is converted to 9-( ⁇ -D-arabinofuranosyl adenine triphosphate [Ara ATP] which is cytotoxic.
  • Other enzyme prodrug combinations include the bacterial (for example from Pseudomonas) enzyme carboxypepcidase G2 with the prodrug para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid. Cleavage of the glutamic acid moiety from this compound releases a toxic benzoic acid mustard; alkaline phosphatase from, for example, calf intestine, will convert inactive phosphorylated compounds such as etoposide-phosphate, doxorubicin- phosphate, mitomycin phosphate, to toxic dephosphorylated metabolites.
  • Penicillin-V amidase will convert phenoxyacetamide derivatives of doxorubicin and melphalan to toxic metabolites and cytosine deaminase (for example from E.coli) will convert 5-fluorocytosine to toxic 5-fluorouracil.
  • genes are ubiquitously expressed. Most genes, however, are expressed in a temporal and/or tissue-specific manner, or are activated in response to extracellular inducers, for example certain genes are actively transcribed only at very precise times in ontogeny in specific cell types or in response to some inducing stimulus. This regulation is mediated in part by the interaction between transcriptional regulatory sequences (which are for example promoter and enhancer regulatory DNA sequences), and sequence-specific, DNA-binding transcriptional protein factors.
  • transcriptional regulatory sequences which are for example promoter and enhancer regulatory DNA sequences
  • Expression cassettes themselves are well known in the art of molecular biology. Such an expression cassette will contain all essential DNA sequences required for expression of the heterologous enzyme in a mammalian cell.
  • a preferred expression cassette will contain a molecular chimaera containing the coding sequence for VZV TK.
  • an appropriate polyadenylation signal for a mammalian gene ie. a polyadenylation signal which will function in a mammalian cell
  • enhancers and promoter sequences in the correct orientation ie. a polyadenylation signal which will function in a mammalian cell.
  • promoters are located immediately upstream (5') from the start site of transcription. Promoter sequences are required for accurate and efficient initiation of transcription. Different gene-specific promoters reveal a common pattern of organisation.
  • a typical promoter includes an AT-rich region called a TATA box (which is located approximately 30 base pairs 5' to the transcription initiation start site) and one or more upstream promoter elements (UPE) .
  • the UPEs are a principle target for the interaction with sequence-specific nuclear transcriptional factors. The activity of promoter sequences are modulated by other sequences called enhancers.
  • the enhancer sequence may be a great distance from the promoter in either an upstream (5') or downstream (3') position.
  • enhancers operate in an orientation- and position-independent manner.
  • the absolute distinction between promoters and enhancers is somewhat arbitrary. Enhancers increase the rate of transcription from the promoter sequence. It is predominantly the interaction between sequence-specific transcriptional factors with the UPE and enhancer sequences that enable mammalian cells to achieve tissue-specific gene expression.
  • transcriptional protein factors tissue-specific, trans-activating factors
  • enhancers cis-acting, regulatory sequences
  • transcriptional regulatory sequence in particular the promoter and enhancer sequence will depend on the targeted cells.
  • Other viruses using specific viral transcriptional regulatory sequences include, but are not limited to, human papilloma virus, Epstein Barr virus, and hepatitis B virus.
  • VZV Varicella zoster virus
  • TK thymidine kinase
  • VZV TK selective expression of VZV TK can be achieved in an HIV infected cell through TAT/TAR interactions.
  • the selective and specific expression of VZV TK will allow the selective production of a cytotoxic or cytostatic compound subsequent to the administration of a nontoxic prodrug.
  • the present invention therefore provides a molecular chimaera comprising a DNA sequence containing the coding sequence of the gene that codes for a heterologous enzyme under the control of the transcriptional regulatory sequence for HIV TAR in an expression cassette.
  • the transcriptional regulatory sequence is thus capable of functioning selectively in a target tissue or cell, for example is capable of transforming an HIV infected cell to selectively express an enzyme for example thymidine kinase.
  • the present invention further provides in a preferred embodiment, a molecular chimaera comprising the transcriptional regulatory sequence for HIV TAR which is selectively activated in mammalian target tissue or cells and is operatively linked to the coding sequence for the gene encoding varicella zoster virus thymidine kinase (VZV TK).
  • VZV TK varicella zoster virus thymidine kinase
  • the transcriptional regulatory sequence comprises a promoter and preferably an enhancer.
  • the present invention provides a molecular chimaera comprising a DNA sequence of the gent coding for the heterologous enzyme, which is preferably VZV TK, including an appropriate polyadenylation sequence, which is linked downstream in a 3' position and in the proper orientation to the transcriptional regulatory sequence for HIV TAR.
  • the DNA sequence encoding a heterologous enzyme is additionally selected from; carboxypeptidase G2 ; alkaline phosphatase; penicillin -V amidase; and non mammalian cytosine deaminase.
  • the promoter and enhancer sequences preferably are selected from the transcriptional regulatory sequence for HIV TAR.
  • the DNA sequence encodes the gene for varicella zoster virus thymidine kinase and is operatively linked to the transcriptional regulatory sequence for HIV TAR.
  • the molecular chimaera of the present invention may be made utilising standard recombinant DNA techniques.
  • the coding sequence and polyadenylation signal of, for example, the VZV thymidine kinase (TK) gene (see Figs. 1A and 1B) are placed in the proper 3' orientation to the essential HIV TAR transcriptional regulator elements.
  • VZV TK gene expression of the VZV TK gene in mammalian cells infected by HIV will enable relatively nontoxic arabinosides and pyrimidines as herein defined to be selectively metabolised to cytotoxic and/or cytostatic metabolites.
  • a method of constructing a molecular chimaera as hereinbefore defined comprising linking a DNA sequence encoding a heterologous enzyme gene, eg. VZV TK to an HIV TAR sequence.
  • a heterologous enzyme gene eg. VZV TK
  • the present invention provides a method of constructing a molecular chimaera as herein defined, the method comprising ligating a DNA sequence encoding the coding sequence and polyadenylation signal of the gene for a heterologous enzyme, (eg. VZV TK) to the transcriptional regulatory sequence (eg. promoter sequence and enhancer sequence) for HIV TAR.
  • a heterologous enzyme eg. VZV TK
  • the VZV thymidine kinase coding sequence and 3' polyadenylation signal reside in an approximately 1,381 bp AccI/Nde I restriction endonuclease fragment (see Figure 1B).
  • VZV TK polyadenylation signal Preferably it is the 1381bp Accl/Nde I fragment containing the VZV TK coding sequence and polyadenylation signal ( Figure 1B) that is ligated to the promoter and enhancer sequences for HIV TAR, although it will be appreciated that other DNA fragments containing the VZV TK gene could be used.
  • the VZV TK polyadenylation signal could be replaced with another suitable polyadenylation signal such as from the SV40 virus or other mammalian genes.
  • molecular chimaeras can be delivered to the target tissue or cells by a delivery system.
  • a delivery system For administration to a host (e.g. mammalian or human) it is necessary to provide an efficient in vivo delivery system which stably integrates the molecular chimaera into the cells.
  • Known methods utilise techniques of calcium phosphate transfection, electroporation, microinjection, liposomal transfer, ballistic barrage or retroviral infection. For a review of this subject see Biotechnique Vol.6. No.7. (1988).
  • retroviral shuttle vectors which are known in the art, (Miller A.D., Buttimore C., Mol. Cell. Biol 6 2895-2902 (1986).
  • retroviral shuttle vectors retroviruses comprising molecular chimaera as used to deliver and stably integrate the molecular chimaera into the genome of the target cell
  • retroviral shuttle vectors are generated using the DNA form of the retrovirus contained in a plasmid.
  • These plasmids also contain sequences necessary for selection and growth in bacteria.
  • Retroviral shuttle vectors are constructed using standard molecular biology techniques well known in the art. Retroviral shuttle vectors have the parental endogenous retroviral genes (eg.
  • Retroviral shuttle vectors have been derived from the Moloney murine leukemia virus (Mo-MLV) but it will be appreciated that other retroviruses can be used such as the closely related Moloney murine sarcoma virus.
  • Other DNA viruses may also prove to be useful as a delivery system.
  • the bovine papilloma virus [BPV] replicates extrachromosomally so that delivery systems based on BPV have the advantage that the delivered gene is maintained in a nonintegrated manner.
  • a retroviral shuttle vector comprising a molecular chimaera as hereinbefore defined.
  • the chimaera comprises a transcriptional regulatory sequence for HIV TAR which is selectively activated in target cells and operatively linked to the coding sequence for the gene encoding the heterologous enzyme VZV TK.
  • the chimaera further comprises a DNA sequence of the coding and polyadenylation sequence of the gene coding for VZV TK linked in a 3' position and in the proper orientation to the transcriptional regulatory sequence for HIV TAR to control expression of the VZV TK gene.
  • the DNA sequence encoding VZV TK is operatively linked to a promoter and to a polyadenylation sequence to control expression of the VZV TK gene.
  • the advantages of a retroviral-mediated gene transfer system are the high efficiency of the gene delivery to the targeted tissue or cells, sequence specific integration regarding the viral genome (at the 5' and 3' long terminal repeat (LTR) sequences) and few rearrangements of delivered DNA compared to other DNA delivery systems.
  • LTR long terminal repeat
  • a retroviral shuttle vector comprising a DNA sequence comprising a 5' viral LTR sequence, a cis acting psi-encapsidation sequence, a molecular chimaera as hereinbefore defined and a 3' viral LTR sequence ( Figure 2 ) .
  • the molecular chimaera is placed in opposite transcriptional orientation to the 5' retroviral LTR ( Figure 2).
  • a dominant selectable marker gene may also be included which is transcriptionally driven from the 5' LTR sequence.
  • Such a dominant selectable marker gene may be the bacterial neomycin-resistance gene NEO (Aminoglycoside 3' phospho- transferase type II), which confers on eukaroytic cells resistance to the neomycin analogue Geneticin (antibiotic G418 sulphate; registered trademark of GIBCO) ( Figure 2).
  • NEO Aminoglycoside 3' phospho- transferase type II
  • the NEO gene aids in the selection of packaging cells which contain these sequences (see below).
  • the retroviral vector used in the examples is based on the Moloney murine leukemia virus but it will be appreciated that other vectors may be used.
  • Such vectors containing a NEO gene as a selectable marker have been described, for example, the N2 vector (Eglitin M.A. et al., Science 230 : 1395-1398 (1985)).
  • retroviral shuttle vectors A theoretical problem associated with retroviral shuttle vectors is the potential of retroviral long terminal repeat (LTR) regulatory sequences transcriptionally activating a cellular oncogene at the site of integration in the host genome. This problem may be diminished by creating SIN vectors ( Figure 2).
  • SIN vectors are self- inactivating vectors which contain a deletion comprising the promoter and enhancer regions in the retroviral LTR.
  • the LTR sequences of SIN vectors do not transcriptionally activate 5' or 3' genomic sequences.
  • the transcriptional inactivation of the viral LTR sequences diminishes insertional activation of adjacent target cell DNA sequences and also aids in the selected expression of the delivered molecular chimaera.
  • SIN vectors are created by removal of approximately 299 bp in the 3' viral LTR sequence (Gilboa E. et al., Biotechniques 4 504-512 (1986))
  • the retroviral shuttle vector of the present invention are SIN vectors. Since the parental retroviral gag, pol and env genes have been removed from these shuttle vectors, a helper virus system may be utilised to provide the gag, pol and env retroviral gene products in trans to package or encapsidate the retroviral vector into an infective virion. This is accomplished by utilising specialised "packaging" cell lines, which are capable of generating infectious, synthetic virus yet are deficient in the ability to produce any detectable wild-type virus. In this way the artificial synthetic virus contains a chimaera of the present invention packaged into synthetic artificial infectious virions free of wild-type helper virus.
  • helper virus that is stably integrated into the packaging cell contains the viral structural genes, but is lacking the psi-site, a cis acting regulatory sequence which must be contained in the viral genomic RNA molecule for it to be encapsidated into an infectious viral particle.
  • an infective virion comprising a retroviral shuttle vector as hereinbefore described, said vector being encapsidated within viral proteins to create an artificial infective, replication-defective retrovirus.
  • the retroviral shuttle vector comprises a shuttle vector comprising a molecular chimaera having the transcriptional regulatory sequence of HIV TAR.
  • the retroviral shuttle vector contains an HIV TAR/VZV TK molecular chimaera.
  • infective virions of the present invention by delivering the artificial retroviral shuttle vector comprising a molecular chimaera of the invention, as hereinbefore described, into a packaging cell line.
  • the packaging cell line may have stably integrated within it a helper virus lacking a psi site and other regulatory sequence as hereinbefore described, or alternatively the packaging cell line may be engineered so as to contain helper virus structural genes within its genome.
  • helper virus LTR regulatory sequences can be made to ensure that the helper virus is not packaged in virions and is blocked at the level of reverse transcription and viral integration.
  • helper virus structural genes i.e. gag, pol and env
  • helper virus structural genes may be individually and independently transferred into the packaging cell line. Since these viral structural genes are separated within the packaging cell's genome, there is little chance of covert recombinations generating wild- type virus.
  • the present invention further provides an infective virion as hereinbefore described for use in therapy, particularly for use in the treatment of HIV infection and pathobiological conditions associated with HIV infection.
  • VZV thymidine kinase gene is accomplished by utilising tissue-specific, transcriptional regulatory (eg. enhancer and promoter) sequences for HIV TAR target tissues or cells e.g. selectivity may be additionally improved by selective infection of HIV infected cells.
  • the retroviral env gene present in the packaging cell line defines the specificity for host infection.
  • the env gene used in constructing the packaging cell line is modified to generate artificial, infective virions that selectively infect HIV infected cells.
  • a retroviral env gene introduced into the packaging cell may be modified in such a way that the artificial, infective virion's envelope glycoprotein selectively infect HIV infected cells via the specific receptor mediated binding utilised by HIV.
  • modifications of the env gene introduced into the packaging cell may be performed by standard molecular biology techniques well known in the art.
  • the infective virion according to the invention may be formulated by techniques well known in the art and may be presented as a formulation or composition with a pharmaceutically acceptable carrier therefor.
  • Pharmaceutically acceptable carriers in this instance physiologic aqueous solutions, may comprise a liquid medium suitable for use as vehicles to introduce the infective virion into a host.
  • An example of such a carrier is saline.
  • the infective virion may be a solution or suspension in such a vehicle. Stabilisers and antioxidants and/or other excipients may also be present in such pharmaceutical formulations which may be administered to a mammal by any conventional method eg oral or parenteral routes. In particular, the infective virion may be administered by intra-venous or intra-arterial infusion.
  • the invention provides a pharmaceutical formulation or composition comprising an infective virion as hereinbefore described in admixture with a pharmaceutically acceptable carrier.
  • the present invention provides methods of making pharmaceutical formulations and compositions as herein described comprising mixing an artificial infective virion, containing a molecular chimaera as hereinbefore described to a cytotoxic or cytostatic metabolite, with a pharmaceutically acceptable carrier.
  • the present invention further provides the use of compounds of Formula (I) or (II) in the manufacture of a medicament for use in the treatment of HIV infected cells capable of expressing VZV thymidine kinase.
  • R 1 is halo, C 1 -5 alkoxy, halogen-substituted C 1 -5 alkoxy; an amino group which is mono -or di- substituted by C 1 -5 alkyl, C 1 -5 alkyl substituted by one or more fluorine atoms, C 3 -6 , cycloalkyl, or a nitrogen containing heterocycle containing C 4 -4 carbon atoms and optionally a double bond; and R 2 is hydrogen, halo or amino are known as anti VZV and cytomegalovirus agents and their use and synthesis are described in European patent application published under No. 0294114.
  • X represents a vinylene or ethynylene group
  • R 1 represents an oxo or imino group
  • R 2 represents a hydrogen atom, C 1-2 alkyl, C 3-4 branched or cycloalkyl group e.g. isopropyl or cyclopropyl
  • R 3 represents a hydrogen atom or an acyl e.g. C 1-4 alkanoyl or benzoyl group optionally substituted for example by one or more halogen, alkyl, hydroxy or alkoxy substituents
  • R 4 represents a hydrogen atom or a hydroxy group. It will be appreciated that when R 3 is not an acyl group, a compound of Formulae (I) or (II) may exist in its tautomeric form.
  • a particularly preferred compound of Formula (II) is 1-( ⁇ -D-Arabinofuranosyl)-5-propynyluracil.
  • pyrimidine nucleosides and purine arabinosides also include the pharmaceutically acceptable derivatives of such compounds, ie. any pharmaceutically acceptable salt, ester, or salt of such ester, or any other compound which, upon administration to a human subject, is capable of providing (directly or indirectly) the active metabolite or residue thereof.
  • the compound is orally active.
  • Prodrug treatment Subsequent to infection with the infective virion, compounds according to the invention which are described by Formulae (I) and (II) are administered, that specifically require VZV TK activitv for the critical phosphorylation step in anabolism to generate cytotoxic or cvtostatic metabolites.
  • the prodrug compounds which are subsequently converted to cytotoxic or cytostatic metabolites in the target cells, are preferably purine arabinosides or pyrimidine nucleosides. Most preferably 9- ⁇ -D-arabinofuranosyl-6- methoxy-9H-purine and 1-( ⁇ -D-arabinofuranosyl)-5-propynyluracil.
  • the above mentioned prodrug compounds are administered to the host (e.g., mammal or human) between six hours and ten days, preferably between one and five days, after administration of the infective virion.
  • the dose of compound as described by Formulae (I) or (II) to be given will advantageously be in the range 0.1 to 250 mg per kilogram body weight of recipient per day, preferably 0.1 to 100mg per kilogram bodyweight. More preferably the dose is 1 to 40mg per kilogram bodyweight most preferably 15-40mg per kilogram bodyweight.
  • the invention also provides a method of treating a host (e.g., mammal or human) in need of anti HIV treatment which comprises administering to the host, a molecular chimaera, as described herein, which is capable of being selectively activated in the HIV infected cells of the host to express an enzyme, and subsequently administering an agent which is converted in the cells by the enzyme to an agent which is cytotoxic or cytostatic to the cells.
  • a host e.g., mammal or human
  • a molecular chimaera as described herein, which is capable of being selectively activated in the HIV infected cells of the host to express an enzyme, and subsequently administering an agent which is converted in the cells by the enzyme to an agent which is cytotoxic or cytostatic to the cells.
  • the invention further provides a method of treating a host in need of anti-HIV treatment comprising administering to the host an infective virion as described hereinbefore.
  • the infective virion encapsidating a retroviral shuttle vector comprising a molecular chimaera, the chimaera comprising a transcriptional regulatory sequence for HIV TAR which is selectively activated in the cells of the host and operatively linked to a gene encoding a heterologous enzyme: in an amount sufficient to transform the cells so as to express the enzyme, and subsequently administering to the host an amount of a compound which is selectively metabolised in the cells by the enzvme to a cvtotoxic or cvtostatic metabolite.
  • FIGURE LEGENDS a retroviral shuttle vector comprising a molecular chimaera, the chimaera comprising a transcriptional regulatory sequence for HIV TAR which is selectively activated in the cells of the host and operatively linked to a gene encoding
  • Figure 1A Diagram of Varicella Zoster Thymidine Kinase Gene.
  • FIG. 1B VZV TK gene - 1 sequence.
  • Figure 2 Proviral form of retrovirus containing HIV TAR/VZV TK
  • HIV-LTR driven VZV-TK pUCHIV (M. Davis et al PNAS 84, 1978.p 8642-8646.) was digested with Hindlll and BamHI.
  • the HIV LTR was isolated by agarose gel electrophoresis, electoeluted and subcloned into ml3mpl9 (Yanisch-Perron, C. et al 1985 Gene 33:103) (Available from New England Biolabs., Beverly, Massachusetts). Mutations were introduced by oligonucleotide-directed mutagenesis to create an Xhol restriction endonuclease site at the 5' end of the HIV-LTR.
  • the plasmid was designated ml3mpl9*LTR. Mutations were confirmed by sequencing. See Fig 3.
  • pUCHIV was deposited at the American Type Culture Collection, Rockville MD USA (ATCC) on 27th February 1991 under the Budapest Treaty with Accession No. 40982
  • ml3mpl9*LTR was deposited at the American Type Culture Collection, Rockville MD USA (ATCC) on 27th February 1991 under the Budapest Treaty with Accession No. 40984 pCR73 (deposited at ATCC under Number 68077) was digested with BAMHI and Kpnl to enable the isolation of the VZV-TK containing fragment.
  • VZV-TK DNA fragment was subcloned into the BamHI and Kpnl digested m13mp19*LTR plasmid. Plasmids containing the VZV-TK (mp19*LTR/TK) were sequenced to ensure the subcloned DNA integrity. See Fig. 4. mP19*LTR/TK was deposited at the American Type Culture Collection, Rockville MD USA (ATCC) on 27th February 1991 under the Budapest Treaty with Accession No. 40983
  • HIV-LTR/VZV-TK containing DNA was isolated as an Xhol fragment and subcloned into N2(XM5). Plasmids were screened for orientation.
  • Plasmids (denoted N2LTR/TK) were chosen which would allow only HIV-LTR driven VZV-TK expression in TAT expression cell lines. See Fig. 5.
  • N2LTR/TK was deposited at the American Type Culture Collection, Rockville MD USA (ATCC) on 27th February 1991 under the Budapest Treaty with Accession No. 40985

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention se rapporte à des chimères moléculaires et à des virions infectieux, à des procédés destinés à leur préparation, à des compositions pharmaceutiques qui les contiennent, à leur utilisation en thérapie, en particulier la thérapie par promédicament enzymatique dirigé contre un virus et utilisée particulièrement pour le traitement d'une infection par le VIH, et à l'utilisation d'agents qui peuvent être catalysés par une enzyme hétérologue pour former des métabolites cytotoxiques ou cytostatiques, tels que des arabinosides de purine et des pyrimidines substituées, dans la thérapie par promédicament enzymatique dirigé contre un virus chez un hôte mammifère (notamment l'être humain).
EP92905231A 1991-02-27 1992-02-26 Preparation par recombinaison d'une enzyme tar chimere pour une therapie destinee a l'infection par le vih Withdrawn EP0573479A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104165A GB9104165D0 (en) 1991-02-27 1991-02-27 Novel entities for hiv therapy
GB9104165 1991-02-27

Publications (1)

Publication Number Publication Date
EP0573479A1 true EP0573479A1 (fr) 1993-12-15

Family

ID=10690703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92905231A Withdrawn EP0573479A1 (fr) 1991-02-27 1992-02-26 Preparation par recombinaison d'une enzyme tar chimere pour une therapie destinee a l'infection par le vih

Country Status (4)

Country Link
EP (1) EP0573479A1 (fr)
JP (1) JPH06505156A (fr)
GB (1) GB9104165D0 (fr)
WO (1) WO1992015693A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
EP0564645B1 (fr) * 1991-10-30 1999-12-29 Universite Pierre Et Marie Curie Paris Vi Cellules transformees pour la prevention ou le traitement de maladies induites par des virus, notamment retrovirus pathogenes
WO1994016736A1 (fr) * 1993-01-22 1994-08-04 University Research Corporation Localisation d'agents therapeutiques
AU1257495A (en) 1993-11-18 1995-06-06 Chiron Corporation Compositions and methods for utilizing conditionally lethal genes
DE69524740T2 (de) * 1994-05-02 2002-08-14 University Of Washington, Seattle Thymidin-kinase-mutanten
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
WO1995033842A1 (fr) * 1994-06-07 1995-12-14 Immunomedics, Inc. Vecteurs retroviraux sans danger, leur production et utilisation
CN101679472B (zh) * 2007-02-28 2014-07-02 艾伯塔大学校董 用于预防或治疗病毒感染的化合物及其应用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8629892D0 (en) * 1986-12-15 1987-01-28 Wellcome Found Antiviral compounds
GB8712745D0 (en) * 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
CN1038306A (zh) * 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
WO1990007936A1 (fr) * 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9215693A1 *

Also Published As

Publication number Publication date
JPH06505156A (ja) 1994-06-16
WO1992015693A1 (fr) 1992-09-17
GB9104165D0 (en) 1991-04-17

Similar Documents

Publication Publication Date Title
EP0415731B1 (fr) Substances nouvelles pour la thérapie du cancer
EP0832980B1 (fr) Thérapie recombinante des infections et désordres hyperprolifératifs
US5861290A (en) Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
EP0702084B1 (fr) Rétrovirus recombinants
US5997859A (en) Method for treating a metastatic carcinoma using a conditionally lethal gene
CA2158936C (fr) Compositions et procedes d'utilisation de genes a pouvoir letal conditionnel
EP0573479A1 (fr) Preparation par recombinaison d'une enzyme tar chimere pour une therapie destinee a l'infection par le vih
US5698446A (en) Methods and compositions for inhibiting production of replication competent virus
Zhang et al. Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription.
Von Rüden et al. Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA
US6479281B1 (en) Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof
EP2138580B1 (fr) Vecteur pour une thérapie génique
US6004803A (en) Genes encoding HSV1-TK containing a deletion of 5' cryptic promoter sites, vectors and cell lines
KR20050008697A (ko) 개선된 키메라 당단백질 및 슈도타입 렌티바이러스 벡터
CA2289491A1 (fr) Particules de vecteur de retrovirus produites dans un systeme d'expression de baculovirus
US6569679B1 (en) Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
CA2047363C (fr) Therapies a base de recombinaison pour les infections et troubles hyperproliferatifs
CA3235253A1 (fr) Glycoproteines d'enveloppe de retrovirus du koala et leurs utilisations
Yeğin HIV-1 regulatory gene dependent expression of a toxic gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970902